final trials could ease metabolics pain, page-2

I think that people are not paying attention to the full pipe-line of products that Metabolic have and are in the process of testing and trialling. See paragraph below taken from recent posting.

I am in fact more excited and encouraged by the fact that the obesity drug AOD9604 may well be a break through for osteoporosis. Currently as with most competing medications, the contra indications leave a lot to be desired. AOD9604 has exceptional tolerability thus far. Consider that a lot of people taking existing osteoporosis medications are also probably taking a plethora of other drugs, this tolerability has to have huge upside and benefits.

This debilitating bone disease is affecting more and more people (both men and women) worldwide and the age affected is getting younger.

In the quarterly Investor update nubmer 16 22 January 2007, Metabolic states there will be a phase 2 trial subject to approval by regulatory authorities.

Taken from previous poster:
MELBOURNE-BASED biotech Metabolic Pharmaceuticals is developing drugs in the areas of obesity, neuropathic (nerve) pain, osteoporosis, type 2 diabetes together with a novel drug delivery technology.

These medical conditions have immense global significance with large associated markets.

The drug delivery technology has the potential for the efficient oral administration of a number of protein based pharmaceuticals.

With this pipeline and current milestone status for each I think Metabolic is an exceptional company to invest in.